Literature DB >> 19583677

CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.

S K Jin1, T S Kang, S O Eom, J-I Kim, H J Lee, J Roh.   

Abstract

BACKGROUND AND
OBJECTIVE: CYP2C19 is clinically important in Korea because of the relatively high incidence of poor metabolizers in the population. To fully understand the genetic mechanism of the CYP2C19 defect in poor metabolizers, all variants need to be studied simultaneously. The aim of this study was to investigate the usefulness of CYP2C19 haplotypes as a marker of CYP2C19 enzyme activity in Koreans.
METHODS: We analysed the single nucleotide polymorphisms and haplotypes of the CYP2C19 gene in 150 healthy Koreans and found three major (frequency > 0.1) haplotypes (H1, H2 and H3). One oral dose of 40 mg omeprazole (Losec) was administered to 30 subjects grouped as H1/H1, H2/H2, H1/H2, H1/H3 and H2/H3. The pharmacokinetics of omeprazole and its metabolites, 5-hydroxyomeprazole and omeprazole sulphone, in those groups was analysed. RESULTS AND DISCUSSION: The area under the plasma concentration-time curve (AUC(0-->infinity)) and elimination half-life (T(1/2)) of omeprazole were significantly greater in the H2/H2 and H2/H3 groups than in the H1/H1 group (P < 0.05), whereas the metabolic ratios of omeprazole to 5-hydroxyomeprazole were also markedly higher.
CONCLUSION: Although a specific SNP of CYP2C19 may be predictive of enzyme activity, haplotyping is more reliable for identifying poor metabolizers in populations with variant alleles other than CYP2C19*2 and *3 alleles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19583677     DOI: 10.1111/j.1365-2710.2008.01012.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  4 in total

Review 1.  Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.

Authors:  I Fricke-Galindo; C Céspedes-Garro; F Rodrigues-Soares; M E G Naranjo; Á Delgado; F de Andrés; M López-López; E Peñas-Lledó; A LLerena
Journal:  Pharmacogenomics J       Date:  2015-10-27       Impact factor: 3.550

2.  Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.

Authors:  Sheng Feng; Yumi Cleary; Neil Parrott; Pei Hu; Cornelia Weber; Yongqing Wang; Ophelia Q P Yin; Jun Shi
Journal:  Eur J Clin Pharmacol       Date:  2015-03-24       Impact factor: 2.953

3.  Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.

Authors:  Joanne Siok Liu Lim; Natalia Sutiman; Thomas E Muerdter; Onkar Singh; Yin Bun Cheung; Raymond Chee Hui Ng; Yoon Sim Yap; Nan Soon Wong; Peter Cher Siang Ang; Rebecca Dent; Werner Schroth; Matthias Schwab; Balram Chowbay
Journal:  Br J Clin Pharmacol       Date:  2016-03-08       Impact factor: 4.335

4.  Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers.

Authors:  Sunny Park; Yang Jin Hyun; Yu Ran Kim; Ju Hyun Lee; Sunae Ryu; Jeong Mi Kim; Woo Yong Oh; Han Sung Na; Jong Gu Lee; Doo Won Seo; In Yeong Hwang; Zewon Park; In Jin Jang; Jaeseong Oh; Seung Eun Choi
Journal:  J Korean Med Sci       Date:  2017-05       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.